AKAP12 Endogenous Transcripts Suppress The Proliferation, Migration And Invasion Of Colorectal Cancer Cells By Directly Targeting oncomiR-183-5p
Received 6 March 2019
Accepted for publication 15 September 2019
Published 8 October 2019 Volume 2019:12 Pages 8301—8310
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Sanjay Singh
Tingting Hu,1,* Xuan Wu,2,* Ke Li,2 Yuan Li,2 Ping He,3 Zhiyuan Wu,4 Jie Fan,5 Weiwei Liu,2,6 Ming Guan1,4
1Department of Clinical Laboratory, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Central Laboratory and Department of Laboratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, People’s Republic of China; 3Department of Nuclear Medicine, Nanjing Hospital, Nanjing Medical University, Nanjing, People’s Republic of China; 4Department of Clinical Laboratory, Huashan Hospital North, Fudan University, Shanghai, People’s Republic of China; 5Department of Pathology, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 6Department of Laboratory Medicine, Shanghai Skin Disease Hospital, Tongji University, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weiwei Liu
Central Laboratory and Department of Laboratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, No. 301 Middle Yanchang Road, Shanghai, People’s Republic of China
Tel/fax +86-21-6630 6905
Department of Clinical Laboratory, Huashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, People’s Republic of China
Tel/fax +86-21-5288 8048
Purpose: Restoring lost function to suppressor gene products has captured the interest of the research community in the field of gene therapy. AKAP12, also known as Gravin/AKAP250, is a tumor suppressor gene, and its deregulation may be responsible for cancer progression. The aim of this study was to investigate whether AKAP12 mRNA has an anti-cancer function by regulating onco-miRNA expression in colorectal cancer (CRC) cells.
Methods: miRNAs targeting AKAP12 were predicted by bioinformatics analysis and further confirmed by dual-luciferase reporter assays and RT-qPCR. The altered expression of microRNA was validated in early-stage CRC tumor tissues by miRseq. Cell proliferation was measured by Cell Counting Kit-8 (CCK-8) assay. Cell invasion and migration were detected by transwell and wound healing assays, respectively. In vivo experiments were conducted to confirm the in vitro findings.
Results: Among all miRNAs, reversed correlation between AKAP12 expression and miRNA-183-5p expression was most significant. Luciferase assays revealed that AKAP12 directly targeted miR-183-5p. The miRseq data showed that miR-183 was also dysregulated at the early stage of tumor development and upregulated in late sub-stage II CRC patients (P<0.01). Mechanistic analysis both in vitro and in vivo demonstrated that anti-miR-183-5p depressed cell proliferation, migration, and invasion in CRC cells while miR-183-5p overexpression resulted in opposite effects.
Conclusion: Our findings suggested that oncomiR-183-5p promoted the proliferation, migration, and invasion of CRC cells. AKAP12 miRNA-binding elements (MREs) suppressed miRNA-183-5p activities. Any change in expression of AKAP12 thus affected miRNA-183-5p. This may be another anti-tumor mechanism in addition to protein-mediation that regulates tumor suppressor genes.
Keywords: microRNA, cell proliferation, cell migration, cell invasion, AKAP12 endogenous transcripts, colorectal cancer cells, oncomiR-183-5p
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]